摘要:
The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.
摘要:
Die vorliegende Erfindung betrifft BET-proteininhibitorische, insbesondere BRD4-inhibitorische 3,4-Dihydropyrido[2,3-b]pyrazinone mit meta -substituierter aromatischer Amino- oder Ethergruppe der allgemeinen Formel (I), in der A, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 und n die in der Beschreibung angegebenen Bedeutungen haben, pharmazeutische Mittel enthaltend die erfindungsgemäßen Verbindungen sowie deren prophylaktische und therapeutische Verwendung bei hyper-proliferativen Erkrankungen, insbesondere bei Tumorerkrankungen. Desweiteren betrifft diese Erfindung die Verwendung von BET-Proteininhibitoren in viralen Infektionen, in neurodegenerativen Erkrankungen, in inflammatorischen Krankheiten, in atherosklerotischen Erkrankungen und in der männlichen Fertilitätskontrolle.
摘要:
The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine- pyrazolines of general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.